Germany’s merger control landscape is undergoing rapid evolution, with the Federal Cartel Office intensifying its scrutiny of “killer acquisitions”. This includes not only traditional mergers and acquisitions, but also licensing agreements, research and development collaborations, and acqui-hires. The introduction of a transaction value threshold, combined with a broader local nexus test, as well as proposed legislative reforms featuring a call-in power and higher notification thresholds, signals a more proactive approach to preserving competition. This is particularly evident in innovative sectors such as pharmaceuticals and technology.
The Federal Cartel Office’s enhanced focus on killer acquisitions and other transaction types is driving companies to carefully assess the competitive impact of their deals. Amid increasing regulatory vigilance and legal uncertainty, businesses must now consider the potential effects of diverse transaction types on the market. The merger control trends in Germany indicate a shift towards a more nuanced approach, with the authorities seeking to prevent anti-competitive deals that could harm innovation and consumer choice. As a result, companies must be prepared to navigate this evolving landscape and ensure compliance with the changing regulatory requirements.
The proposed legislative reforms aim to strengthen the Federal Cartel Office’s powers to review and intervene in transactions that may pose a threat to competition. The introduction of a light call-in power and higher notification thresholds is expected to enable the authority to focus on the most critical deals and prevent those that could have adverse effects on the market. Companies operating in Germany must stay informed about these developments and adapt their strategies to ensure they are in compliance with the evolving merger control rules. By doing so, they can minimize the risk of regulatory intervention and ensure that their transactions are completed successfully.
